The Effects of the Endocrine System on Endometrial Cancer (Ghrelin)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Endometrial cancer usually begins in the endometrium, which is the tissue lining of the uterus. Endometrial cancer is the most commonly diagnosed gynaecological malignancy in Australia. It affects 1 in 80 Australian women and there are about 1400 new cases and 260 deaths from the disease every year. Most affected women are aged between 50 and 70 years. The purpose of this study is to investigate the possible role of the endocrine system in the regulation of human endometrial cancer. By looking at the laboratory results of people with endometrial cancer and also those without endometrial cancer we hope to gain a better understanding of how endometrial cancer develops and progresses. This may lead to the development of new, effective therapies for endometrial cancer.
| Condition |
|---|
|
Endometrial Cancer |
| Study Type: | Observational |
| Study Design: | Observational Model: Case Control Time Perspective: Prospective |
| Official Title: | Expression and Function of Ghrelin and Its Receptor, Growth Hormone Secretagogue Receptor TWEAK Protein and Its Receptor Fn14 in Human Endometrial Cancer |
Endometrial tissue
| Estimated Enrollment: | 80 |
| Study Start Date: | October 2009 |
| Estimated Study Completion Date: | April 2013 |
| Estimated Primary Completion Date: | October 2012 (Final data collection date for primary outcome measure) |
| Groups/Cohorts |
|---|
|
Grade 2
Patients with Endometrial cancer of Grade 1 differentiation
|
|
Benign
Patients without endometrial cancer
|
|
Grade 1
Patients with Endometrial cancer of Grade 2 differentiation
|
|
Grade 3
Patients with Endometrial cancer of Grade 3 differentiation
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
| Sampling Method: | Non-Probability Sample |
Patients with endometrial cancer and patients who are having a hysterectomy for non-cancerous conditions such as fibroids, chronic pelvis pain or abnormal uterine bleeding are eligible for the study
Inclusion Criteria:
- women aged 18 years or older
- having a hysterectomy for the treatment of endometrial cancer, fibroids, chronic pelvic pain or abnormal uterine bleeding
- have provided informed consent
Contacts and Locations| Contact: Trudi Cattley | trudi_cattley@health.qld.gov.au |
| Australia, Queensland | |
| Greenslopes Private Hospital | Recruiting |
| Greenslopes, Queensland, Australia, 4120 | |
| Contact: Fiona Menzies 3646 4467 fiona_menzies@health.qld.gov.au | |
| Contact: Trudi Cattley 3646 0447 trudi_cattley@health.qld.gov.au | |
| Principal Investigator: Andreas Obermair | |
| Principal Investigator: Chen Chen | |
| Study Chair: | Chen Chen, MD PhD | The University of Queensland |
More Information
No publications provided
| Responsible Party: | Professor Chen Chen, University of Queensland |
| ClinicalTrials.gov Identifier: | NCT01075386 History of Changes |
| Other Study ID Numbers: | Endo01 |
| Study First Received: | February 23, 2010 |
| Last Updated: | June 12, 2012 |
| Health Authority: | Australia: National Health and Medical Research Council Australia: Department of Health and Ageing Therapeutic Goods Administration Australia: Human Research Ethics Committee |
Keywords provided by Queensland Centre for Gynaecological Cancer:
|
Hysterectomy Endometrial cancer Benign Endocrine system Tissue collection |
Additional relevant MeSH terms:
|
Endometrial Neoplasms Sarcoma, Endometrial Stromal Adenoma Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms |
Uterine Diseases Genital Diseases, Female Neoplasms, Complex and Mixed Neoplasms by Histologic Type Sarcoma Neoplasms, Connective and Soft Tissue Endometrial Stromal Tumors Neoplasms, Glandular and Epithelial |
ClinicalTrials.gov processed this record on May 22, 2013